Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals today announced that it will host a key opinion leader (KOL) webinar to discuss the unmet medical need in migraine management and the potential role for rofecoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment landscape on Tuesday, October 25, 2022, at 11:00 AM Eastern Time. A live Q&A session will follow the formal presentation.
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine. Previously marketed as VIOXX, rofecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile in multiple indications, including acute migraine.